Amit J. Sabnis

Amit J. Sabnis

Auto-generated profile, based on publicly available information

Amit J. Sabnis

Lurie Children's Hospital 1 Chicago, IL

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LLLuping Lin
Luping Lin
ASAmit J Sabnis
Amit J Sabnis
ECElton Chan
Elton Chan
VOVictor Olivas
Victor Olivas
LCLindsay Cade
Lindsay Cade
TBTrever Bivona
Trever Bivona

20 July 2008 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KMKelly A McGowan
Kelly A McGowan
JLJun Z Li
Jun Z Li
CPChristopher Y Park
Christopher Y Park
VBVeronica Beaudry
Veronica Beaudry
HTHolly K Tabor
Holly K Tabor
GBGregory S Barsh
Gregory S Barsh

24 August 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
GHGorjan Hrustanovic
Gorjan Hrustanovic
VOVictor Olivas
Victor Olivas
EPEvangelos Pazarentzos
Evangelos Pazarentzos
ATAsmin Tulpule
Asmin Tulpule
SASaurabh Asthana
Saurabh Asthana
TBTrever Bivona
Trever Bivona

31 August 2018 in Science
Verified
Journal Article
Closed access
PDF file
LBL. J. Bugaj
L. J. Bugaj
ASA. J. Sabnis
A. J. Sabnis
AMA. Mitchell
A. Mitchell
JGJ. E. Garbarino
J. E. Garbarino
JTJ. E. Toettcher
J. E. Toettcher
WLW. A. Lim
W. A. Lim
Dynamics of cell signaling and decoding: Defects in cellular signaling pathways, like those in some cancer cells, are often thought to result in increased or decreased steady-state signals that promote or inhibit cell proliferation. But Bugaj et al. show that dynamic changes in the duration or frequency of a signal can also alter cellular responses (see the Perspective by Kolch and Kiel). They took precise control of signaling in cultured human or mouse cells with a light-controlled mechanism for activating and inactivating the guanosine triphosphate Ras. Known cancer mutations in components of the Ras-activated signaling pathway or inhibitors of particular pathway components altered signal timing and readouts. The modified dynamics changed transcriptional outcomes and could inappropriately support cell proliferation. The ability to probe responses of signaling networks in this way may enhance understanding of biological regulation and reveal new therapeutic targets. Science , this issue p. eaao3048 ; see also p. 844

1 April 2009 in Cancer Cell
Verified
Journal Article
Closed access
MSMarianne Santaguida
Marianne Santaguida
KSKoen Schepers
Koen Schepers
BKBryan King
Bryan King
ASAmit J. Sabnis
Amit J. Sabnis
EFE. Camilla Forsberg
E. Camilla Forsberg
EPEmmanuelle Passegué
Emmanuelle Passegué

17 March 2009 in PLOS Biology
Verified
Journal Article
Open access
PDF file
ASAmit J Sabnis
Amit J Sabnis
LCLaurene S Cheung
Laurene S Cheung
MDMonique Dail
Monique Dail
HKHio Chung Kang
Hio Chung Kang
MSMarianne Santaguida
Marianne Santaguida
BBBenjamin S Braun
Benjamin S Braun
How oncogenes modulate the self-renewal properties of cancer-initiating cells is incompletely understood. Activating KRAS and NRAS mutations are among the most common oncogenic lesions detected in human cancer, and occur in myeloproliferative disorders (MPDs) and leukemias. We investigated the effects of expressing oncogenic KrasG12D from its endogenous locus on the proliferation and tumor-initiating properties of murine hematopoietic stem and progenitor cells. MPD could be initiated by KrasG12D expression in a highly restricted population enriched for hematopoietic stem cells (HSCs), but not in common myeloid progenitors. KrasG12D HSCs demonstrated a marked in vivo competitive advantage over wild-type cells. KrasG12D expression also increased the fraction of proliferating HSCs and reduced the overall size of this compartment. Transplanted KrasG12D HSCs efficiently initiated acute T-lineage leukemia/lymphoma, which was associated with secondary Notch1 mutations in thymocytes. We conclude that MPD-initiating activity is restricted to the HSC compartment in KrasG12D mice, and that distinct self-renewing populations with cooperating mutations emerge during cancer progression. Ras proteins act as molecular switches that relay growth signals from outside the cell. This mechanism is often subverted in cancer, and Ras proteins are activated directly by RAS gene mutations in approximately one-third of human malignancies. We have modeled this in mice engineered to have a Ras mutation. These mice develop a disease similar to chronic leukemias in humans called myeloproliferative disorders. It is marked by a fatal accumulation of mature and immature cells in the blood and bone marrow. We investigated whether some or all of these neoplastic cells were immortal. In agreement with the “cancer stem cell” hypothesis, we found that immortal cells were extremely rare in the bone marrow of diseased mice. They were found only in the same cell populations that contain normal bone marrow stem cells. However, these cells had high rates of replication and produced large numbers of daughter cells. Furthermore, many mice went on to develop acute lymphoid leukemia after acquiring additional mutations in maturing lymphoid cells. These studies exemplify the evolution of malignant stem cells during cancer progression. They also highlight the importance of rare, long-lived cells in the genesis and, potentially, therapy of high-risk chronic leukemias caused by abnormal Ras proteins.